Obiettivo Influenza is a recurrent global threat and affects millions of people in Europe and the world every year. The Universal Vaccine project is highly original and brings together European state-of-the-art scientists in order to develop a powerful new mucosal vaccine for humans providing life-long protection against influenza. In the longer perspective, the project may contribute to the objective of reducing or even eradicating influenza disease in humans.The Universal Vaccine project combines European SMEs and RTD performers that have pioneered the development of new vaccines and vaccine formulations, and which possess unique IPR related to new components and procedures that can be used for safer and more effective vaccination strategies. Arexis (SE) is the IPR holder of CTA1-DD, which is a new highly potent mucosal adjuvant. Pepscan (NL) has unique knowledge and IPR related to peptides and peptidomimetics while Proxima Concepts (UK) has the exclusive IPR related to a proprietary delivery technology. The unique collaboration between these SMEs and VIB/University of Ghent (BE), the IP holder of M2e-based influenza vaccines, Eurogentec (BE) and Göteborg University (SE) has the potential of resulting in important breakthroughs in European vaccine development research.The unique combination of the three SMEs for the rational design of a mucosal influenza vaccine is unprecedented in European vaccine research. A successful novel mucosal vaccine against influenza would have significant impact on the global market and secure the growth and development of the European vaccine industry. If successful, Arexis, Pepscan and Proxima will establish themselves firmly on the market for mucosal vaccines, and their extended and potentially stronger IP would allow for an expansion of their respective business markets. Campo scientifico natural sciencesbiological sciencesmicrobiologyvirologynatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health scienceshealth sciencesinfectious diseasesRNA virusesinfluenzamedical and health sciencesbasic medicineimmunologymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programma(i) FP6-SME - Horizontal research activities involving SMEs: Specific activities covering wider field of research under the Focusing and Integrating Community Research programme 2002-2006. Argomento(i) SME-1 - Co-operative Research (all areas of science and technology) Invito a presentare proposte FP6-2003-SME-1 Vedi altri progetti per questo bando Meccanismo di finanziamento Cooperative - SMEs-Co-operative research contracts Coordinatore BIOVITRUM AB Contributo UE Nessun dato Indirizzo Arvid Wallgrens Backe 20 GÖTEBORG Svezia Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato Partecipanti (6) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto AREXIS AB Svezia Contributo UE Nessun dato Indirizzo Arvid Wallgrens Backe 20 GÖTEBORG Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato EUROGENTEC SA Belgio Contributo UE Nessun dato Indirizzo Rue Bois Saint Jean 5, Liege Science Park, SERAING Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato GÖTEBORG UNIVERSITY Svezia Contributo UE Nessun dato Indirizzo Vasaparken GÖTEBORG Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato PEPSCAN SYSTEMS B.V. Paesi Bassi Contributo UE Nessun dato Indirizzo Edelhertweg 15 2098 LELYSTAD Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato PROXIMA CONCEPTS LTD Regno Unito Contributo UE Nessun dato Indirizzo c/o London BioScience Innovation Centre, 2 Royal College Street LONDON Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE, VZW Belgio Contributo UE Nessun dato Indirizzo Rijvisschestraat 120 ZWIJNAARDE Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato
